The Hippo signaling effector WWTR1 is a metastatic biomarker of gastric cardia adenocarcinoma

BackgroundGastric cardia adenocarcinoma (GCA) is an aggressive subtype of gastric cancer with a high metastatic rate. However, the metastatic biomarker of GCA has not been established.MethodsTo search for the biomarker for GCA metastasis, we here examined expression of the Hippo signaling effector WWTR1 (WW domain containing transcription regulator 1, commonly listed as TAZ) in tumor tissue samples from 214 GCA cases using the tissue microarray assay (TMA), and statistically analyzed association of the WWTR1 expression with metastasis-related pathological outcomes and cumulative survival of the GCA patients. Furthermore, shRNA knockdown was used to determine the role of WWTR1 in promoting cell migration in gastric cancer cells.ResultsThe results have shown that WWTR1 is overexpressed in 66.4% of the GCA tumor samples. Expression of WWTR1 has a significant inverse correlation with cumulative survival of GCA patients (p < 0.01). WWTR1 positive patients had a mean survival of 56.9 ± 4.4 months, comparing to WWTR1 negative mean survival of 77.3 ± 5.9 months. More importantly, expression of WWTR1 significantly associated with tumor invasion and metastasis (in T stage, p = 0.031; N stage, p < 0.01; and TNM stage, p < 0.001). Furthermore, knockdown of WWTR1 impaired migration of gastric cancer AGS cells.ConclusionsOur studies have identified WWTR1 as a metastatic biomarker of GCA for poor prognosis, defined a role of WWTR1 in driving metastasis of gastric cancer, and suggested WWTR1 as a potential target for anti-metastatic therapy of GCA.

[1]  John M. Lamar,et al.  YAP/TAZ Activation as a Target for Treating Metastatic Cancer , 2018, Cancers.

[2]  I. Vitale,et al.  The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications , 2015, Expert Reviews in Molecular Medicine.

[3]  K. Tanaka,et al.  Prognostic differences of adenocarcinoma arising from the cardia and the upper third of the stomach. , 1993, The American surgeon.

[4]  Zhongwei Lv,et al.  Expression of the c-Met Proto-Oncogene and Integrin α5β1 in Human Gastric Cardia Adenocarcinoma , 2012, Bioscience, biotechnology, and biochemistry.

[5]  H. Katayama,et al.  HER2 Expression in Carcinomas of the True Cardia (Siewert Type II Esophagogastric Junction Carcinoma) , 2014, World Journal of Surgery.

[6]  H. Ji,et al.  A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. , 2014, Cancer cell.

[7]  M. Feith,et al.  Adenocarcinoma of the Esophagogastric Junction: Results of Surgical Therapy Based on Anatomical/Topographic Classification in 1,002 Consecutive Patients , 2000, Annals of surgery.

[8]  S. Bicciato,et al.  The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells , 2011, Cell.

[9]  K. Guan,et al.  The Hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1 , 2015, Cell Research.

[10]  Nicola Elvassore,et al.  Role of YAP/TAZ in mechanotransduction , 2011, Nature.

[11]  Christian N. Cunningham,et al.  Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors , 2018, Cancers.

[12]  Zhengyu Zha,et al.  TAZ Promotes Cell Proliferation and Epithelial-Mesenchymal Transition and Is Inhibited by the Hippo Pathway , 2008, Molecular and Cellular Biology.

[13]  Jun Yang,et al.  Expression of SIRT1 in Gastric Cardiac Cancer and Its Clinicopathologic Significance , 2011, International journal of surgical pathology.

[14]  T. Vaughan,et al.  Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. , 2013, Seminars in radiation oncology.

[15]  Ying Wang,et al.  Microarray expression profile analysis of long non-coding RNAs of advanced stage human gastric cardia adenocarcinoma , 2013, Molecular Genetics and Genomics.

[16]  M. Sudol,et al.  Geranylgeranylation signals to the Hippo pathway for breast cancer cell proliferation and migration , 2014, Oncogene.

[17]  Xiaoshan Feng,et al.  Down-regulation of C/EBP homologous protein (CHOP) expression in gastric cardia adenocarcinoma: Their relationship with clinicopathological parameters and prognostic significance. , 2015, Clinics and research in hepatology and gastroenterology.

[18]  W. Guo,et al.  Methylation‐mediated repression of GADD45A and GADD45G expression in gastric cardia adenocarcinoma , 2013, International journal of cancer.

[19]  K. Guan,et al.  The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. , 2012, Seminars in cell & developmental biology.

[20]  Stefano Piccolo,et al.  YAP/TAZ at the Roots of Cancer. , 2016, Cancer cell.

[21]  Zhengyu Zha,et al.  TEAD Transcription Factors Mediate the Function of TAZ in Cell Growth and Epithelial-Mesenchymal Transition* , 2009, Journal of Biological Chemistry.

[22]  Xiaohua Li,et al.  Reduction of TIP30 correlates with poor prognosis of gastric cancer patients and its restoration drastically inhibits tumor growth and metastasis , 2009, International journal of cancer.

[23]  Xiang-Dong Fu,et al.  Regulation of the Hippo-YAP Pathway by G-Protein-Coupled Receptor Signaling , 2012, Cell.

[24]  H. Lee,et al.  TAZ responds to fluid shear stress to regulate the cell cycle , 2018, Cell cycle.

[25]  Xiaolong Yang,et al.  Roles of the Hippo pathway in lung development and tumorigenesis , 2016, International journal of cancer.

[26]  Wannian Yang,et al.  Nedd4-1 is an exceptional prognostic biomarker for gastric cardia adenocarcinoma and functionally associated with metastasis , 2014, Molecular Cancer.

[27]  O. Carpén,et al.  EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus , 2016, BMC Cancer.

[28]  Z. Dong,et al.  FBXO32, a new TGF-β/Smad signaling pathway target gene, is epigenetically inactivated in gastric cardia adenocarcinoma. , 2015, Neoplasma.

[29]  Jan Hasenauer,et al.  Evaluation of epidermal growth factor receptor signaling effects in gastric cancer cell lines by detailed motility-focused phenotypic characterization linked with molecular analysis , 2017, BMC Cancer.

[30]  Zhou Zhou,et al.  siRNA targeting YAP gene inhibits gastric carcinoma growth and tumor metastasis in SCID mice , 2016, Oncology letters.

[31]  Yan Zhou,et al.  A functional polymorphism in MIR196A2 is associated with risk and prognosis of gastric cancer , 2013, Molecular carcinogenesis.

[32]  Lincoln D. Stein,et al.  A Metastatic Mouse Model Identifies Genes That Regulate Neuroblastoma Metastasis. , 2017, Cancer research.

[33]  Frederic A. Fellouse,et al.  The Hippo pathway regulates Wnt/beta-catenin signaling. , 2010, Developmental cell.

[34]  Jia Wen Liang,et al.  Aberrant methylation‐mediated downregulation of long noncoding RNA C5orf66‐AS1 promotes the development of gastric cardia adenocarcinoma , 2018, Molecular carcinogenesis.

[35]  D. Papachristou,et al.  Adenocarcinoma of the Gastric Cardia The Choice of Gastrectomy , 1980, Annals of surgery.

[36]  W. Guo,et al.  Aberrant methylation and loss expression of RKIP is associated with tumor progression and poor prognosis in gastric cardia adenocarcinoma , 2013, Clinical & Experimental Metastasis.

[37]  J. Cui,et al.  Differential expression of Pim-3, c-Myc, and p-p27 proteins in adenocarcinomas of the gastric cardia and distal stomach , 2014, Tumor Biology.

[38]  Fa-Xing Yu,et al.  Targeting the Hippo Pathway for Anti-cancer Therapies. , 2015, Current medicinal chemistry.

[39]  Miao Chen,et al.  CYR61 (CCN1) is a metastatic biomarker of gastric cardia adenocarcinoma , 2016, Oncotarget.

[40]  E. Montgomery,et al.  The Hippo Pathway in Human Upper Gastrointestinal Dysplasia and Carcinoma: A Novel Oncogenic Pathway , 2007, International journal of gastrointestinal cancer.

[41]  Y. Maehara,et al.  Clinicopathologic characteristics and outcome of adenocarcinoma of the human gastric cardia in comparison with carcinoma of other regions of the stomach. , 1995, Journal of the American College of Surgeons.

[42]  W. Hong,et al.  TEADs Mediate Nuclear Retention of TAZ to Promote Oncogenic Transformation* , 2009, Journal of Biological Chemistry.

[43]  M. Tsao,et al.  TAZ is a novel oncogene in non-small cell lung cancer , 2011, Oncogene.

[44]  R. Aqeilan,et al.  NEDD4 E3 ligase inhibits the activity of the Hippo pathway by targeting LATS1 for degradation , 2013, Cell cycle.

[45]  W. Guo,et al.  Decreased expression and frequent promoter hypermethylation of RASSF2 and RASSF6 correlate with malignant progression and poor prognosis of gastric cardia adenocarcinoma , 2016, Molecular carcinogenesis.